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ABSTRACT 14 
Adenoviruses are efficient gene delivery vectors based on their ability to transduce a 15 
wide variety of cell types and drive high-level transient transgene expression. Whilst 16 
there have been advances in modifying human adenoviral (HAdV) vectors to 17 
increase their safety profile, there are still pitfalls that need to be further addressed. 18 
Pre-existing humoral and cellular immunity against common HAdV serotypes limits 19 
the efficacy of gene transfer and duration of transgene expression. As an alternative, 20 
non-human adenoviral (NHAdV) vectors can circumvent neutralizing antibodies 21 
against HAdVs in immunised mice and monkeys and in human sera suggesting 22 
NHAdV vectors could circumvent pre-existing humoral immunity against HAdVs in a 23 
clinical setting. Consequently, there has been an increased interest in developing 24 
NHAdV vectors for gene delivery in humans. In this review, we outline the recent 25 
advances and limitations of HAdV vectors for gene therapy and describe examples of 26 
NHAdV vectors focusing on their immunogenicity, tropism, and potential as effective 27 
gene therapy vehicles. 28 
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1. INTRODUCTION 36 
Adenoviruses (AdVs) are non-enveloped viruses with an icosahedral capsid 37 
containing a double stranded linear DNA genome of 26 to 46 kb (Davison et al., 38 
2003). Since their discovery in 1950s in human cell cultures (Rowe et al., 1953), 39 
AdVs have been identified in many species, ranging from fish to humans. Today 40 
AdVs form five accepted genuses (Mastadenovirus, Aviadenovirus, Siadenovirus, 41 
Atadenovirus, and Ichtadenovirus) within the family Adenoviridae. Recently, one 42 
more genus was proposed, named Testadenovirus (Doszpoly et al., 2013). So far 57 43 
different AdV serotypes (Lukashev et al., 2008; Walsh et al., 2011) have been 44 
isolated from humans (HAdVs) and are classified within the genus Mastadenovirus 45 
as 7 species, HAdV A through HAdV G (Jones et al., 2007). Whilst classification was 46 
previously based on biological characteristics (erythrocyte agglutination, 47 
oncogenicity, and by specific anti-sera neutralisation), phylogenetic relationships 48 
have been revised and clarified on the basis of genotype similarity (Bailey & Mautner, 49 
1994; Davison et al., 2003). Accordingly, individual AdV serotypes frequently share 50 
characteristics such as tropism and associated host pathologies with other serotypes 51 
within their species. The tropism is in large part determined by the capsid proteins 52 
which interact with the host cell surface receptors to mediate cell entry. The capsid 53 
consists primarily of hexon and penton proteins which form pentameric structures at 54 
each of the 12 vertices, securing a trimeric fibre that projects outwards. Other viral 55 
proteins include the cement proteins (IIIa, VI, VIII, and IX) and the core proteins (TP, 56 
V, VII, and mu) that associate with the AdV genome (Vellinga et al., 2005). Whilst the 57 
basic structure of these proteins is maintained, variations in the length and 58 
composition of the amino acid sequences of these proteins across species and 59 
genera cause them to bind to a number of receptors and host factors with variable 60 
affinity. Thus, the coxsackie and adenovirus receptor (CAR), CD46, desmoglein-2 61 
(DSG2), CD80, CD86, vascular cell adhesion molecule-1 (VCAM-1), heparan sulfate 62 
proteoglycans (HSPGs), major histocompatibility complex class I-2 (MHC-I-2), 63 
sialic acid (SA), dipalmitoylphosphatidylcholine (DPPC), lactoferrin and others can be 64 
utilised by one or more HAdV serotypes to transduce cells (Sharma et al., 2009b; 65 
Arnberg, 2012).  66 
Viral vectors remain to be the most promising gene transfer vehicles for gene therapy 67 
due to their higher gene-transfer efficiencies when compared with other approaches. 68 
Currently AdV vectors have been used in 23.5% of all clinical trials 69 
(http://www.wiley.com//legacy/wileychi/genmed/clinical/) as they can efficiently 70 
transduce a wide variety of dividing and quiescent  cells, they very rarely integrate 71 
into the host genome minimising the risk of insertional mutagenesis (Stephen et al., 72 
2010), they have a large packaging capacity up to 36 kb and they can routinely be 73 
produced at high titres. Of the 57 HAdV serotypes, HAdV-5 of species C has been 74 
the best characterised and the most widely used in clinical trials so far, mainly in the 75 
treatment of cancer (http://www.wiley.com//legacy/wileychi/genmed/clinical/) but also 76 
as a vaccine (Sullivan et al., 2003; Shiver & Emini, 2004).  77 
It has, however, been estimated that over 80% of the adult population have been 78 
naturally exposed to the common HAdV serotypes (Garnett et al., 2002). As a result, 79 
pre-existing humoral and cellular immunity may preclude efficient gene transfer 80 
(Kuriyama et al., 1998) and local systemic immune responses against the vector and 81 
transgene product may result in a number of clinically undesirable side-effects. 82 
Severe immune responses against AdV vectors can have serious consequences in 83 
humans, which have been exemplified by a fatal case of systemic inflammatory 84 
response syndrome that was directly attributed to the systemically administered AdV 85 
gene transfer vector (Raper et al., 2003). Moreover, upon systemic administration of 86 
recombinant HAdV-5, transduction of immune cells in the liver and spleen leads to 87 
immune responses against the AdV vector that can limit its therapeutic efficacy. 88 
Eliminating liver tropism and the epitopes involved in viral proteins recognition by 89 
neutralizing antibodies (NAbs) has been proposed to reduce these immune 90 
responses. Taking advantage of the diversity of AdVs capsid protein isoforms and 91 
their variety of ligand-receptor interactions, vectors based on low seroprevalent AdVs 92 
could potentially enable targeting to different cell types as well as overcoming pre-93 
existing immunity. Naturally, non-human AdV (NHAdV) species have a low 94 
seroprevalence in all human populations and therefore represent a source of 95 
potential vectors that could fit this niche. Since the beginning of their development in 96 
1990s (Mittal et al., 1995), recombinant NHAdV vectors have been derived from 97 
many different AdV species: canine AdV-2 (CAdV-2), bovine AdV-3 (BAdV-3), 98 
porcine AdV-3 (PAdV-3), ovine AdV-7 (OAdV-7), murine AdV-1 (MAdV-1), several 99 
simian (SAdVs) and fowl (FAdVs) AdVs. Here we outline the current status of HAdV 100 
vectors, summarise the development of NHAdV vectors and discuss the advantages 101 
and shortfalls of each. 102 
 103 
2. INNATE AND ADAPTIVE IMMUNE RESPONSES AGAINST ADENOVIRUSES 104 
Innate and adaptive immune responses play a critical role in resolving AdV infections. 105 
The presence of specific anti-viral antibodies significantly increases antibody 106 
constant fraction receptors (FcR)-dependent viral internalization in macrophages, 107 
triggering an innate immune response to AdVs which leads to type I Interferon (IFN) 108 
production and caspase-dependent interleukin (IL)-1β maturation (Zaiss et al., 2009). 109 
Internalized AdV DNA induces maturation of pro-IL-1β in macrophages dependent on 110 
NALP3 and ASC, components of the innate cytosolic molecular complex called the 111 
inflammasome, but independent of Toll-like receptors (TLRs) and IFN regulatory 112 
factors (Muruve et al., 2008). Later studies reported that this response requires the 113 
binding of the arginine-glycine-aspartic acid (RGD) motif in the AdV penton base with 114 
macrophage 3 integrins (Di Paolo et al., 2009). Barlan and colleagues also 115 
demonstrated that the specific AdV penetration mechanism of the endosomal 116 
membranes is required for IL-1β release (Barlan et al., 2011a,b). Macrophages and 117 
conventional dendritic cells (cDCs) can detect cytosolic AdV DNA in a TLR9 118 
independent manner (Basner-Tschakarjan et al., 2006; Zhu et al., 2007) whilst 119 
plasmacytoid DCs (pDCs) detect non-methylated AdV CpG-containing DNA in the 120 
endosomes through TLR9. Also, internalised HAdV-5 and HAdV-6 immune 121 
complexes have been reported to induce DC maturation via TLR9 agonist motifs 122 
present in the AdV genome, whereas HAdV-35, -36 and -26 have a limited potency 123 
to induce DC maturation due to having a smaller number of motifs (Perreau et al., 124 
2012). TLR9 signalling pathway is dependent on myeloid differentiation primary 125 
response 88 (MyD88) (Yamaguchi et al., 2007; Zhu et al., 2007) and induces the 126 
secretion of IL-6 and IL-12 (Yamaguchi et al., 2007). Heparin-sensitive receptors on 127 
DCs bind to the AdV shaft fiber region and trigger T cell immune responses (Cheng 128 
et al., 2007). HAdV-5-induced Natural Killer (NK) cell activation relies on T cell 129 
contribution in vitro (Pahl et al., 2012), and also appears to be related to presence of 130 
type I IFN in vivo (Zhu et al., 2007, 2008). In contrast to HAdV-5, in response to 131 
HAdV-35 pDCs alone are sufficient for NK cell activation in a TLR9-dependent 132 
manner, after which NK cells enhance pDCs IFN- secretion (Pahl et al., 2012). This 133 
indicates that both pDCs and T cells may be necessary for NK cells activation. 134 
Therefore, it is clear that different AdV serotypes can trigger immune responses in 135 
different ways, thus it is essential to study immune responses in detail to ensure that 136 
efficient strategies to circumvent immune responses are developed. The complement 137 
system also plays a critical role in AdV immune responses with effects mediated 138 
through the classical and alternative complement pathway. The complement system 139 
appears to be related to humoral immune responses to the vector capsid or the 140 
encoded transgene (Appledorn et al., 2008). IgM isotype neutralization of virions 141 
activates the classical complement pathway hampering receptor-ligand interactions 142 
with the target cell (Xu et al., 2013). On the other side, AdV-induced 143 
thrombocytopenia has been demonstrated to be dependent on factor B and C3 of the 144 
alternative complement pathway, and AdVs mediate induction of the nuclear factor-145 
kappaB (NF-κB) upon binding to C3 (Appledorn et al., 2008). In addition to 146 
macrophages, DCs and NK cells, binding of CAR protein and v-integrins on non-147 
immune cells also activates immune responses (Liu et al., 2005; Schoggins et al., 148 
2005). In particular, CAR-mediated responses have been reported in epithelial cells 149 
(Tamanini et al., 2006) and integrin-mediated responses in kidney epithelium-derived 150 
(REC) cells, inducing expression of CXCL10 (IP-10) through NF-κB in a RGD motif-151 
dependent manner (Liu et al., 2005). 152 
These anti-AdV innate immune responses are linked to adaptive immune responses 153 
through direct interactions and production of cytokines (Ginsberg, 1996; Appledorn et 154 
al., 2008). When a cell is infected by AdVs, it releases type I ( and ) IFN. 155 
Plasmacytoid DCs, cDCs, and macrophages produce IFN- upon AdV recognition. 156 
The surrounding uninfected cells recognize IFN by IFN receptors and they induce, via 157 
the Jak-STAT signalling pathway, the expression of anti-viral enzymes such as MxA, 158 
2’,5’-oligoadenylate synthase and protein kinase R (PKR) (Katze et al., 2002). Also, 159 
Type I IFN induces up-regulation of co-stimulatory molecules in DCs such as CD80, 160 
CD86 and CD40, leading to DCs maturation (Vujanovic et al., 2009). Moreover, IFN 161 
takes part in B cells activation for antibody production. Type II IFN (IFN-) is an 162 
immunoregulatory cytokine secreted by Th1-type T CD4+ cells, T CD8+ cells and NK 163 
cells. IFN- induces the expression of major histocompatibility complex class I (MHC-164 
I) on nearly all cells and major histocompatibility complex class II (MHC-II) on 165 
professional antigen presenting cells (APCs) promoting antigen presentation to 166 
helper T CD4+ cells, and it also activates macrophages (Gattoni et al., 2006). 167 
Dendritic cells have been shown to engulf infected cells and present antigens to 168 
naive T CD8+ cells through MHC-I (Albert et al., 1998). At the same time, APCs 169 
present antigens to Th1-type T CD4+ cells through MHC-II and upon activation they 170 
produce IL-2. If the T CD8+ cell receives both antigen presence and IL-2 signal it 171 
gets activated (Jankovic et al., 2001). Once the T CD8+ cell interacts with an infected 172 
cell, mainly recognizing conserved epitopes in hexon protein (Olive et al., 2002; Leen 173 
et al., 2004; Tang et al., 2006), it begins a cytotoxic response leading to apoptosis of 174 
the infected cell (Schumacher et al., 2004). On the other hand, Th2-type T CD4+ 175 
cells induce B cell maturation and isotype switching (Jankovic et al., 2001). 176 
Neutralizing antibodies (NAbs), mostly IgG isotype, interact with AdV capsid proteins 177 
(Gall et al., 1996; Sumida et al., 2005). It was reported that NAbs recognize mainly 178 
the hypervariable regions (HVRs) of the hexon protein (Roberts et al., 2006; Abe et 179 
al., 2009; Shiratsuchi et al., 2010; Bradley et al., 2012b) and to a lesser extent the 180 
fiber knob domain (Myhre et al., 2007; Bradley et al., 2012a; Yu et al., 2013) and 181 
penton base proteins (Yu et al., 2013). AdV neutralization prevents cell attachment 182 
and facilitates aggregation and phagocytosis mediated by opsonisation (Wohlfart, 183 
1988). FcRs in macrophages and NK cells recognize NAbs bound to AdV antigens, 184 
facilitating their phagocytic and cytolytic action, respectively (Gattoni et al., 2006). 185 
In summary, AdV gene transfer vectors are subjected to anti-viral immune responses 186 
(Figure 1) once administered to the patient. This process highly limits their efficiency 187 
for gene therapy applications. Therefore it is critical to understand the immune 188 
response to AdVs and have strategies to circumvent anti-viral immune responses. 189 
These will be discussed in the following sections, focusing in the main limiting factors: 190 
NAbs against AdV proteins and CD8+ cytotoxic T lymphocytes (CTLs) against 191 
infected cells. 192 
 193 
3. IMPLICATIONS OF ANTI-VIRAL IMMUNE RESPONSES AGAINST HUMAN 194 
ADENOVIRAL VECTORS AND STRATEGIES TO CIRCUMVENT IT 195 
Since the tragic death of a patient participating in a clinical gene therapy trial 196 
involving administration of a replication-incompetent HAdV-5 vector (Raper et al., 197 
2003), many efforts have been made to avoid anti-viral immune responses against 198 
AdV vectors to improve their safety and efficacy. Since the AdV vectors recognition 199 
by the immune system depends on the existence of antigenic epitopes in the AdV 200 
proteins (i.e. NAbs recognize AdV proteins, and CD8+ CTLs recognize infected 201 
cells), most of the strategies to circumvent the immunogenicity of HAdV vectors are 202 
based on protein modifications.  203 
Functionally significant HAdV-5-specific NAbs are directed primarily against the 204 
HAdV-5 hexon protein and to a lesser extent to fiber and penton base proteins (Gall 205 
et al., 1996; Sumida et al., 2005; Tian et al., 2011). Despite several groups 206 
successfully generated hexon-chimeric HAdV-5 vectors that partially evaded anti-207 
HAdV-5 immune responses (Gall et al., 1998; Roy et al., 1998; Ostapchuk & Hearing, 208 
2001; Wu et al., 2002; Roberts et al., 2006; Bruder et al., 2012), hexon pseudotyping 209 
appears to be a limited strategy as it has been reported the formation of many non-210 
viable virions (Youil et al., 2002).  211 
The hexon protein (Rux & Burnett, 2000) contains 7 HVRs (Crawford-Miksza & 212 
Schnurr, 1996). Many groups have exchanged HAdV-5 HVRs with those from low 213 
prevalent serotypes and demonstrated that the resultant AdV vector can evade 214 
HAdV-5 immunity (Roberts et al., 2006; Abe et al., 2009; Shiratsuchi et al., 2010). 215 
Roberts et al showed that HAdV-5 with all seven HVRs replaced with the 216 
corresponding ones from the rare serotype HAdV-48 could circumvent HAdV-5 NAbs 217 
in both mice and rhesus monkeys (Roberts et al., 2006). Further studies (Bradley et 218 
al., 2012b) exchanged only some HVRs and demonstrated that HAdV-5-specific 219 
NAbs target multiple HVRs, suggesting that mutation or replacement of all 7 HVRs 220 
would probably be necessary to evade anti-HAdV-5 immunity. However, in 2012, 221 
Coughlan et al demonstrated that, despite HAdV-5 containing all seven HVRs from 222 
HAdV-48, it displayed a decreased hepatocyte transduction and accumulation in 223 
Kupffer cells, and it triggered a robust pro-inflammatory response not present with the 224 
wild-type HAdV-48 (Coughlan et al., 2012). In order to generate novel viable HVR-225 
chimeric vectors able to evade immune responses, it would be necessary to use 226 
HVRs from other serotypes, and for that it is essential to determine the viability of 227 
HVR replacements in AdV vectors based on the structural and biochemical 228 
constraints of the different HVRs that limit their manipulation.  229 
Regarding the immunogenicity of the fiber protein, little is known about the epitopes 230 
involved in fiber recognition by NAbs, although it is thought that anti-knob NAbs 231 
represent the major population of anti-fiber NAbs (Myhre et al., 2007; Bradley et al., 232 
2012a; Yu et al., 2013). It has been reported that fiber pseudotyping of AdV vectors 233 
can lead to reduced AdV-associated innate (Schoggins et al., 2005) and adaptive 234 
immune responses (Parker et al., 2009; Rogée et al., 2010). Despite the C-terminal 235 
and shaft region heterogeneity, the N-terminal region (fiber tail) that is bound to 236 
penton base protein presents high similarity amongst diverse AdV species 237 
(Tarassishin et al., 2000). Thus, designing chimeric AdV vectors containing all 238 
proteins from HAdV-5 but fibers from other serotypes (mainly species B and D) is a 239 
very interesting approach to retarget HAdV-5 to different tissues while circumventing 240 
anti-viral pre-existing immunity. Thus, several chimeric AdV vectors with tropism for 241 
different cell types such as HAdV-5/3 (Haviv et al., 2002; Kanerva et al., 2002; Volk 242 
et al., 2003 ; Ulasov et al., 2007), HAdV-5/11 (Havenga et al., 2001; Stone et al., 243 
2005; Wang et al., 2011b), HAdV-5/16 (Havenga et al., 2001) and HAdV-5/35 244 
(Havenga et al., 2001) were generated. Interestingly, HAdV-5/35 and -5/11 were 245 
assessed in vivo in murine and non-human primate animal models, showing reduced 246 
toxicity and limited induction of inflammatory cytokines (Ni et al., 2005). However, 247 
other studies showed that HAdV-5/35 presented tropism for CD34+ human 248 
hematopoietic stem cells in vitro (Shayakhmetov et al., 2000), monocytes, 249 
granulocytes and blast cells of human bone marrow (Rogozhin et al., 2011), and 250 
CD4+ and CD8+ T lymphocytes in vitro (Zhang et al., 2013b). Since transduction of 251 
immune cells can lead to immune responses, extensive characterization of chimeric 252 
AdV vectors is essential.  253 
Other retargeting strategies such as the truncation or removal of the fiber knob 254 
domain and its replacement with foreign trimerization motifs and heterologous 255 
peptides fused to the fiber shaft are also recently being assessed (fiber de-knobbing) 256 
(Coughlan et al., 2010). Despite the removal of the fiber knob domain results in lower 257 
number of fiber copies per virion leading to a less efficient production of the AdV 258 
vector, this approach has been shown that may contribute to evade NAbs (Myhre et 259 
al., 2007).  260 
Regarding the adaptive immunity mediated by CD8+ CTLs, the response depends on 261 
viral antigenic epitopes loaded in the MHC of the infected cell. High-capacity, helper-262 
dependent (HD) or also called gutless vectors bypass this problem (Kochanek et al., 263 
1996) as they are devoid of all viral genes and, therefore, they are less immunogenic 264 
and allow long-term transgene expression (Maione et al., 2001; Ehrhardt & Kay, 265 
2002; Dudley et al., 2004). Furthermore, as in these vectors DNA is constituted of 266 
stuffer DNA as part of the vector backbone to maintain optimum vector size, non-267 
methylated viral CpG-containing DNA (recognized by DCs through TLR9) can be 268 
eliminated. However, one study showed that HD AdVs also trigger an innate immune 269 
response dependent on TLR9 (Cerullo et al., 2007). Despite the advantages they 270 
offer, HD vectors are equally neutralized by pre-existing antibodies against capsid 271 
proteins and also may present transgene-encoded proteins immunogenicity (Tripathy 272 
et al., 1996).  273 
On the other hand, the activation of immune responses due to interactions between 274 
AdV capsid proteins and receptors in the target cell can limit AdV vector efficacy in 275 
gene therapy applications. HAdV-5 binds to the CAR protein on human erythrocytes 276 
in the bloodstream, limiting its delivery to the in vivo target tissue and contributing to 277 
toxicity (Seiradake et al., 2009). To avoid this interaction, Nicol et al. described two 278 
CAR-binding mutations that abolished the previously described agglutination in 279 
human and rat erythrocytes (Nicol et al., 2004). Moreover, HAdV-5 binding to CAR 280 
activates immune responses that can limit its potential as a gene transfer vector 281 
(Schoggins et al., 2005; Tamanini et al., 2006). Other interactions such as RGD with 282 
macrophage 3 integrins (Cheng et al., 2007; Di Paolo et al., 2009) or the one 283 
between the shaft fiber region and the heparin-sensitive receptor from DCs (Cheng et 284 
al., 2007) have also been associated with immune responses and, in the case of 285 
RGD motif, through IL-1 production (Di Paolo et al., 2009). Interestingly, the 286 
mutation of the RGD motif to arginine-glycine-glutamic acid (RGE) resulted in a 287 
significant 5-fold reduction in spleen uptake diminishing the anti-viral inflammatory 288 
response after intravascular administration (Bradshaw et al., 2012). These studies 289 
indicate that de-targeting from native receptors could be a useful approach to avoid 290 
immune responses against the AdV vector. Nevertheless, further research needs to 291 
be done to describe the pathways through which the AdV vectors trigger immune 292 
responses. There are more factors involved in cellular recognition that could also be 293 
implicated in promotion of immune responses. These include alternative receptors 294 
and co-receptors such as FcR (Xu et al., 2008), complement-3 receptor (CR-3) (Xu et 295 
al., 2008), HSPGs and low-density lipoprotein receptor-related protein (LRP) 296 
(Shayakhmetov et al., 2005), complement receptor-1 (CR1) (Carlisle et al., 2009), 297 
scavenging receptor-A (SR-A) (Khare et al., 2012), bridging molecules such as the 298 
coagulation factor IX, X, VII and protein C (Parker et al., 2006), complement 299 
component C4-binding protein (C4BP) (Shayakhmetov et al., 2005) and IgM 300 
antibodies (Xu et al., 2008). Further studies will have to be done in order to describe 301 
their influence in the use of HAdV vectors for gene therapy applications. 302 
Apart from genetic engineering of HAdV vectors, other strategies such as chemical 303 
modifications by addition of cationic polymers or lipid molecules to shield AdV vectors 304 
and prevent them from binding undesired proteins have been widely studied. Several 305 
variants of polyethylene glycol (PEG) have been used but better shielding was found 306 
with multivalent copolymers of poly[N-(2-hydroxypropyl)methacrylamide] (pHPMA). 307 
Shielding of HAdV vectors with pHPMA showed an increased biological stability of 308 
the vector and a longer persistence in blood, decreased liver transduction and 309 
therefore a lower immune response (Green et al., 2004). Furthermore, coated HAdV 310 
vectors have been shown to be less vulnerable to recognition by pre-existing NAbs in 311 
vitro (Romanczuk et al., 1999; Wang et al., 2011a) and by Kupffer cells in the liver 312 
(Mok et al., 2005), likely due to the hampered interaction of PEGylated AdVs and 313 
Kupffer cells SR-A (Haisma et al., 2009). However, other factors could be affecting 314 
liver transduction of the coated HAdV such as the limited size of the sinusoidal 315 
endothelial cells fenestrae (Hofherr et al., 2008). The use of PEGylated HAdV vectors 316 
resulted in decreased levels of IL-6 production in vitro (Mok et al., 2005) and of IL-6 317 
and IL-12 in vivo (Croyle et al., 2000). Moreover, coated HAdV vectors induce lower 318 
IL-6 levels in serum due to decreased levels of spleen AdV uptake (De Geest et al., 319 
2005). Furthermore, several groups successfully retargeted coated AdV vectors 320 
(Parker et al., 2005; Stevenson et al., 2007; Morrison et al., 2008, 2009; Wang et al., 321 
2010). Although in some studies they presented similar levels of anti-tumoral efficacy 322 
(Morrison et al., 2009) or transgene expression (Parker et al., 2005; Stevenson et al., 323 
2007; Morrison et al., 2008; Wang et al., 2010) to unmodified wild-type HAdV-5, 324 
others achieved a greater therapeutic effect with negligible side effects (Eto et al., 325 
2010; Yao et al., 2010). Despite the limited retargeting efficiency in comparison with 326 
unmodified HAdV-5, the use of PEGylated AdV vectors achieved lower hepatic 327 
tropism and reduction in liver and spleen toxicity in vivo. Moreover, evidence 328 
highlights the potential of AdV polymer coating strategies to circumvent pre-existing 329 
immunity to all viral capsid proteins (Romanczuk et al., 1999; Croyle et al., 2000; De 330 
Geest et al., 2005; Mok et al., 2005; Haisma et al., 2009; Zeng et al., 2012). 331 
Nevertheless, the reported PEG immunogenicity could hamper PEGylated AdVs 332 
efficacy (Shimizu et al., 2012). 333 
Despite the advances made in HAdV vectors to evade anti-AdV immune responses, 334 
the current strategies are limited by the formation of non-viable virions following 335 
molecular engineering and by the limited knowledge and characterization of capsid 336 
epitopes motifs responsible for cross-reactivity. Therefore, the use of low 337 
seroprevalent HAdV serotypes has been proposed as an alternative to hexon or 338 
fiber-chimeric AdV vectors in order to circumvent pre-existing NAbs. More than 15 339 
years ago, several studies showed that the alternate use of AdV vectors from 340 
different serotypes, even within the same AdV species, can circumvent anti-AdV 341 
humoral immunity (Kass-Eisler et al., 1996; Mastrangeli et al., 1996; Mack et al., 342 
1997; Parks et al., 1999). A study on the presence of NAbs against different HAdV 343 
serotypes in the Belgium population reported high seroprevalence towards species A, 344 
C, and E, while low seroprevalence towards species B and D, among which, 345 
serotypes 11, 34, 35, 50 (species B), 43 and 48 (species D) showed the lowest 346 
values (Vogels et al., 2003). This indicates that these serotypes could be potentially 347 
used to evade pre-existing immunity. Vectors have been developed from multiple 348 
HAdV serotypes with lower seroprevalence than HAdV-5: HAdV-11 (Holterman et al., 349 
2004; Stone et al., 2005; Abbink et al., 2007), HAdV-35 (Gao et al., 2003; Sakurai et 350 
al., 2003; Seshidhar Reddy et al., 2003; Vogels et al., 2003; Barouch et al., 2004; Wu 351 
& Tikoo, 2004; Abbink et al., 2007; Brouwer et al., 2007; Sakurai, 2008; Sakurai et 352 
al., 2009; McVey et al., 2010; Geisbert et al., 2011), HAdV-49 (Lemckert et al., 2006; 353 
Abbink et al., 2007), HAdV-26, -48 and -50 (Abbink et al., 2007; Geisbert et al., 354 
2011), HAdV-7 (Nan et al., 2003) and HAdV-6 (Capone et al., 2006). However, since 355 
the presence of NAbs depends on AdV exposure which is closely related to 356 
geographical location, seroprevalence studies in different specific populations are 357 
very important. Moreover, better characterization of such serotypes in terms of 358 
tropism and specificity, biodistribution and toxicity is yet required to design safe HAdV 359 
vectors. 360 
 361 
4. USE OF NON-HUMAN ADENOVIRAL VECTORS 362 
The idea about NHAdVs as vectors appeared in 1990s, with the assumption they 363 
would be more useful for vaccines and gene therapeutic approaches in human 364 
medicine than HAdV-based vectors. Design and characterization of NHAdV vectors 365 
was reviewed earlier (Bangari & Mittal, 2006), with a focus on vaccine vectors. In this 366 
review we focus on the progress in development of NHAdV vectors (Table 1) for 367 
gene therapy. 368 
4.1 CANINE AdV VECTORS  369 
Canine AdV (genus Mastadenovirus, species CAdV A) derived vectors are currently 370 
the best described NHAdV vectors. Up to 90% of the residues involved in CAdV-2 371 
fiber tail-penton base interactions are conserved compared to HAdV-5 (Schoehn et 372 
al., 2008). CAdV-2 binds to CAR (Tomko et al., 1997; Soudais et al., 2000) but it 373 
does not contain an integrin-interacting RGD motif in the penton base (Chillon & 374 
Kremer, 2001) in contrast with HAdV-5 (Greber, 2002). CAdV-2 penton base appears 375 
to be ~20% shorter than that of HAdV-5 (Schoehn et al., 2008). In addition, CAdV-2 376 
has shorter protuberances on the top of the penton base, mainly where RGD motif is 377 
contained in HAdVs, and a shorter N-terminal region. The hypervariable loops in the 378 
hexon protein are shorter in CAdV-2 and the protruding structures containing the 379 
epitopes recognised by anti-hexon HAdV-5  antibodies are absent, whilst the fiber is 380 
more complex since the shaft region contains two bends (Schoehn et al., 2008). Also, 381 
protein IX and IIIa are shorter in CAdV-2 (Schoehn et al., 2008). Production of CAdV-382 
2 vectors started more than 15 years ago (Klonjkowski et al., 1997) in an attempt to 383 
avoid the inhibitory effect of the pre-existing humoral and cellular immunity against 384 
HAdVs when used in the clinics. Later, it was shown that CAdV-2 vectors rarely 385 
cause neither the activation and proliferation of T cells nor the maturation of DCs 386 
(Perreau & Kremer, 2006). The advantage of these vectors over HAdV vectors is that 387 
CAdV-2 mainly interacts with CAR (Soudais et al., 2000) and they present specific 388 
tropism for neurons in the central nervous system (Soudais et al., 2001) with great 389 
capacity for axonal transport in vivo. Taking into account that CAdV-2 vectors 390 
development was recently reviewed (Bru et al., 2010), the following data will focus on 391 
the more recent trials performed with the mentioned vector. Until very recently, the 392 
production of CAdV-2 vectors was based on dog kidney (DK) cell lines (Kremer et al., 393 
2000), which is not accepted by the Food and Drug Administration (FDA) and the 394 
European Medicine Agency (EMA). To circumvent this problem,  CAdV-2 E1-395 
transcomplementing cell lines, based on Madin-Darby canine kidney (MDCK) cells 396 
accepted by the FDA and EMA for the production of vaccines, have been developed 397 
(Fernandes et al., 2013a). CAdV-2 vector DNA replication in the MDCK-E1 cell line 398 
was shown to correlate with the expression levels of the transcomplementing E1A 399 
and E1B. Whilst Cre recombinase expression in MDCK-E1-Cre cell lines (for HD 400 
CAdV-2 vectors production) can impair cell growth, controlled expression of Cre was 401 
determined not to result in negative effects on viral production (Fernandes et al., 402 
2013b). CAdV-2 based vectors are ideally suited for treating neurological disorders, 403 
but due to vector titer limitations, large volumes are necessary for applicability in the 404 
clinics. Therefore, better purification and scalable production according to good 405 
manufacturing practice (GMP) are being currently developed (Segura et al., 2012; 406 
Fernandes et al., 2013a) and the improvement of producer cell lines have increased 407 
vector titers (Ibanes & Kremer, 2013). In a comparative study on HD HAdV, HD 408 
CAdV-2 and a VSV-G lentiviral vector, the transduction efficiency and transgene 409 
expression in human midbrain neuroprogenitor cells was assessed. HD CAdV-2 was 410 
determined to have the most promising vector profile: equal transduction efficacy, no 411 
negative effect to neuronal development and milder induced immune response 412 
(Piersanti et al., 2013). HD CAdV-2 was also used as a vector in order to evaluate a 413 
gene therapy approach to correct the neurodegenerative lysosomal storage disorder 414 
mucopolysaccharidosis type IIIa (Lau et al., 2012). It was shown to effectively 415 
transduce neurons and provide long term transgene expression, however its use in 416 
vivo was limited to discrete areas of the brain, indicating a need to find a way to 417 
increase transgene expression throughout the whole brain. Furthermore, in a 418 
clinically relevant stroke model in rats, cortical CAdV-2 vector injection transduced 419 
neurons at a greater level and covered a larger region than lentiviral vectors (Ord et 420 
al., 2013), reducing infarct volume and improving neurologic recovery. For all the 421 
potential of CAdV-2 vectors, there ultimately remains the need for further 422 
understanding of the effects of CAdV-2 vectors on human cells before they are able 423 
to enter human clinical trials. 424 
4.2 BOVINE AdV VECTORS 425 
Bovine AdVs (genus Mastadenovirus, species BAdV A, B, C; genus Atadenovirus, 426 
species BAdV D) were the first NHAdVs used for vectoring purposes. Mittal and 427 
colleagues substituted the non-essential E3 region of BAdV-3 (BAdV B species) with 428 
the firefly luciferase reporter gene and luciferase expression lasted at least 6 days 429 
post-infection in human embryonic kidney (HEK)293 cells (Mittal et al., 1995). BAdV-430 
3 might be a better option to target a specific tissue or organ, since its cell entry is 431 
independent of CAR (Bangari et al., 2005b) and other primary receptors of HAdV-5 432 
(Bangari et al., 2005a). BAdV-3 uses sialic acid molecules as a primary receptor to 433 
enter into host cells (Li et al., 2009) and it can efficiently transduce different cell types 434 
of various species. However, it shows limitations in transducing human cell lines 435 
(Rasmussen et al., 1999; Wu & Tikoo, 2004; Bangari et al., 2005b). To circumvent 436 
this problem, capsid proteins (fiber and pIX) were genetically modified to increase the 437 
ability of BAdV-3 to transduce non-bovine cells (Zakhartchouk et al., 2007). Studies 438 
on BAdV-3 vectors in vivo biodistribution in a mouse model showed efficient 439 
transduction of the heart, kidney, and lung in addition to liver and spleen with a 440 
longer duration and higher levels of transgene expression than HAdV-5 vectors 441 
(Sharma et al., 2009a). In a mouse model of breast cancer, the biodistribution of 442 
BAdV-3 vector was comparable to that of HAdV-5 vectors, the vector had the ability 443 
to efficiently transduce tumor and systemic tissues in the presence of HAdV-5 444 
immunity, and it evaded sequestration by Kupffer cells (Tandon et al., 2012). Also, it 445 
has been shown that there is minimal cross-neutralization by pre-existing anti-HAdV 446 
immunity in humans (Bangari et al., 2005b). These results show the suitability of 447 
BAdV-3 vectors as a delivery system for cancer gene therapy while circumventing 448 
pre-existing anti-vector immunity. Moreover, BAdV-3 and HAdV-5 vectors have a 449 
comparable biological behaviour in human, bovine, porcine and mouse cell lines and 450 
both genomes persist at high levels in vector-permissive cell lines in the absence of 451 
immune pressure, proving BAdV-3 vectors safety for their use as gene delivery 452 
vehicles (Sharma et al., 2011).  453 
4.3 PORCINE AdV VECTORS 454 
The idea of using PAdV (genus Mastadenovirus, species Porcine A, B, C) vectors 455 
was published over 20 years ago (Tuboly et al., 1993). A few years later it was 456 
discovered that the virus can enter but is unable to replicate in dog, sheep, bovine 457 
and human cells (Reddy et al., 1999a). Soon after, PAdV-3 (PAdV A species) vectors 458 
were constructed with the long-term objective to develop replication-competent 459 
PAdV-3 as a live gene transfer vector to induce a mucosal immune response in pigs 460 
(Reddy et al., 1999b). Recombinant PAdV-3 is an effective delivery system in pigs 461 
(Hammond & Johnson, 2005) and it is often studied together with BAdV-3 vectors, 462 
showing similar properties: lack of cross-neutralization with pre-existing anti-HAdV 463 
immunity in humans (Bangari & Mittal, 2004; Bangari et al., 2005b), CAR and integrin 464 
independent cell entry (Bangari & Mittal, 2005; Bangari et al., 2005b), similar safety 465 
profile and biological characteristics (Sharma et al., 2011), efficient transduction of 466 
several cell types of various species with PAdV-3 having an advantage in specific 467 
targeting of the breast tissue (Bangari et al., 2005b), and the vector genomes remain 468 
as linear episomes (Sharma et al., 2009a). In contrast with BAdV-3 vectors, the 469 
genome levels of PAdV-3 vector were shown to be comparable or lower than those of 470 
HAdV-5 vectors in vivo in a mouse model, except in the case of the heart where the 471 
levels were comparable or higher (Sharma et al., 2009a). The specificity of PAdV 472 
vectors for distinct tissues is very interesting for the design of vectors for targeted 473 
gene delivery. 474 
4.4 SIMIAN AdV VECTORS 475 
Simian AdVs are grouped into several human (certain HAdV species contain simian 476 
or ape AdVs, based on species-demarcation criteria like phylogenetic distance, 477 
nucleotide composition etc.) and simian AdV species within the genus 478 
Mastadenovirus. The first gene transfer vector derived from chimpanzee AdV-68 479 
(ChAdV-68/Pan 9/SAdV-25; species HAdV E) was able to grow in HEK293 480 
complementing cells without being neutralized by antibodies against HAdV serotypes 481 
(Farina et al., 2001). Since neutralizing seroprevalence to ChAdV-68 in different 482 
regions of the world is significantly lower than that to HAdV-5 (Xiang et al., 2006; 483 
Ersching et al., 2010; Zhang et al., 2013a), that makes it a good candidate for 484 
application in humans. Interestingly a single surface loop defines a major 485 
neutralization site for the ChAdV-68 hexon (Pichla-Gollon et al., 2007), which when 486 
mutated, permitted the virus to escape from neutralization by polyclonal antisera 487 
obtained from animals in vitro. This was actually the first neutralizing site identified for 488 
any AdV, which was later very important for the successful application of the vectors 489 
in the clinics. Gene delivery by ChAdV-68 is CAR-dependent (Cohen et al., 2002), 490 
and unlike the E1 of HAdV-5, the flanking sequences of ChAdV-68 are non- 491 
homologous with cell-derived E1, preventing the formation of replication-competent 492 
viruses (Xiang et al., 2002). Development of vectors derived from chimpanzee AdVs 493 
Pan 5 (ChAdV-5/SAdV-22), Pan 6 (ChAdV-6/SAdV-23), and Pan 7 (ChAdV-7/SAdV-494 
24), members of HAdV E species, started in 2004 (Roy et al., 2004). The vectors 495 
transduced skeletal muscle with the same efficiency as HAdV-5 vectors, but without 496 
being neutralized by human sera, and the neutralization domains showed to be 497 
different in Pan 6 and Pan 7 both in vitro and in vivo. One study investigated the 498 
importance of neutralizing determinants on capsid proteins by using chimeric vectors 499 
with different combinations of Pan 7 and Pan 6 penton base, hexon and fiber proteins 500 
(Roy et al., 2005), reporting that both hexon and fiber have neutralization epitopes 501 
and that in vivo transduction was more affected by anti-hexon antibodies, with no 502 
effect of anti-penton base NAbs. Other studies on seroprevalence rates of various 503 
ChAdVs were carried out, with Pan 6 and Pan 7  seeming promising as gene therapy 504 
vectors although depending on the region where the potential patients live (Jian et 505 
al., 2013). A tropism modified derivative of Pan 7 showed several advantages over 506 
HAdV-5 for the use in gene therapy: lower degree of inactivation, diminished liver 507 
transduction caused by poor stability of FX-Pan 7 complexes, greater gene delivery 508 
efficiency than the wild-type control Pan 7 vector in vitro, and higher transduction in 509 
vivo of the Her2 (human epidermal growth factor receptor type 2)-expressing human 510 
tumor cells injected intravenously in mice but not statistically significant compared to 511 
the control (Belousova et al., 2010). The last finding indicates that there is a need to 512 
improve the vector to achieve the desired levels of target specific transduction. Pan 6 513 
vector demonstrated a better capacity than HAdV-5 vector in transduction of brain 514 
tumor cells and glioma cells, indicating that it is a promising vector candidate for the 515 
brain tumor therapy (Skog et al., 2007). Twenty E1 deleted vectors were generated 516 
from different AdVs isolated from chimpanzees, bonobos and gorillas, of which 12 517 
could be propagated, rescued and expanded in HEK293 cells (Roy et al., 2011b). 518 
SAdV-7 (HAdV G species) was proposed for vectoring a few years earlier 519 
(Purkayastha et al., 2005b), and was subsequently constructed as an E1-deleted 520 
vector which could be complemented by HAdV-5 E1 genes in HEK293 cells (Roy et 521 
al., 2011a). The latter observation was surprising since SAdVs from HAdV G species 522 
are phylogenetically quite distant from HAdV C members. Recently it was shown that 523 
humans have low seroreactivity against simian (SAdV-11, -16) or chimpanzee-524 
derived (ChAdV-3, -63) AdV vectors compared with HAdV vectors (rHAdV-5, -28, -525 
35) across multiple geographic regions (Quinn et al., 2013). Chimpanzees and 526 
macaques elicited a systemic humoral but not systemic cellular immune response to 527 
endogenous AdVs. The structure of the E3 locus, involved in modulating the host's 528 
response to infection, is smaller in HAdVs than in ape AdVs, which may impact the 529 
ability of the ape AdVs to evade host immune detection and elimination (Calcedo et 530 
al., 2009). ChAdV-68 showed the ability to transduce immature and mature human 531 
DCs, followed by secretion of IFN-α and IL-6 but not IL-12 or tumor necrosis factor 532 
(TNF)-α, and transduced immature DCs could stimulate proliferation of autologous T 533 
lymphocytes (Varnavski et al., 2003). Therefore, ChAdV-68 could be used as a 534 
vector for transduction of human DCs. 535 
4.5 FOWL AdV VECTORS 536 
Construction of FAdV (genus Aviadenovirus, species FAdV A to FAdV E) vectors 537 
started with the demonstration that recombinant FAdV-10 (FAdV C species) could be 538 
used to express an antigen to induce a protective immune response in pathogen-free 539 
chickens (Sheppard et al., 1998). After the identification of FAdV-9 (species FAdV D) 540 
regions that are non-essential for the virus (Ojkic & Nagy, 2001, 2003; Corredor & 541 
Nagy, 2010a), FAdV-9 recombinants demonstrated wild-type growth kinetics, virus 542 
titers, cytopathic effect and plaque morphology (Corredor & Nagy, 2010a), 543 
expression in avian and mammalian cells, and lack of replication in mammalian cells, 544 
indicating their applicability as gene delivery vehicles for mammalian systems 545 
(Corredor & Nagy, 2010b). FAdV-8 (species FAdV E) vectors were also constructed 546 
and showed efficacious in vivo delivery of antibody fragments against pathogenic 547 
infectious bursal disease virus (IBDV) (Greenall et al., 2010). FAdV-1 (species FAdV 548 
A) or CELO (Chicken Embryo Lethal Orphan) vectors have been widely used. The 549 
genomic regions that could be deleted were evaluated more than 10 years ago and a 550 
cosmid-based strategy was developed for generating CELO vectors (Michou et al., 551 
1999; François et al., 2001). FAdV-1 has several interesting properties: it interacts 552 
with CAR and its capsid architecture allows changes in its tropism (Tan et al., 2001), 553 
it transduces mammalian cells as efficiently as HAdV-5 vector and has a potential for 554 
mammalian gene transfer applications, especially because it has larger DNA 555 
packaging capacity and greater physical stability (Michou et al., 1999). It was shown 556 
that FAdV-1 is able to deliver p53 transgene into various tissues in vivo restoring p53 557 
function in human tumor cells xenografts in mice and leading therefore to the 558 
inhibition of tumor growth (Logunov et al., 2004). Moreover, FAdV-1 encoding human 559 
IL-2 gene can successfully produce biologically active recombinant IL-2 in vitro, in 560 
ovo, and in vivo, and it is capable of increasing the median survival time of mice 561 
carrying melanoma tumors (Shmarov et al., 2002; Cherenova et al., 2004). Also, 562 
recombinant FAdV-1 encoding the HSV-1 thymidine kinase showed cytotoxicity in 563 
carcinoma cell lines and suppressed tumor growth and increase median of survival of 564 
mice with melanoma tumors (Shashkova et al., 2005), demonstrating its efficacy for 565 
the gene delivery to tumor cells in vitro and in vivo. Furthermore, one study showed 566 
that FAdV-1 successfully enhanced expression levels of secreted alkaline 567 
phosphatase reporter gene in transduced mammalian cells in vitro and in vivo 568 
(Tutykhina et al., 2008). Finally, PEGylated and retargeted with fibroblast growth 569 
factor FAdV-1 showed increased levels of binding and internalization in a variety of 570 
human cell lines (Stevenson et al., 2006), with transgene expression being greater 571 
than the unmodified version in PC-3 human prostate cells, and being fully resistant to 572 
inhibition by human serum in vitro (Stevenson et al., 2006). All together indicates that 573 
retargeting of CELO virus to human cells via disease-specific receptors is possible, 574 
while avoiding pre-existing humoral immunity. 575 
4.6 OVINE AdV VECTORS 576 
The production of OAdV (genus Mastadenovirus, species OAdV A, B; genus 577 
Atadenovirus, species OAdV D) vectors started more than 15 years ago (Xu et al., 578 
1997) after determining the non-essential regions within the genome (Vrati et al., 579 
1996). Surprisingly, much larger insertions than expected are tolerated, and portions 580 
of sequences can be deleted without affecting virus viability (Xu et al., 1997). The 581 
primary receptor for OAdV-7 (OAdV D species) is not CAR, as it was shown that 582 
OAdV-7 does not compete with HAdV-5 for the entry into cells (Xu & Both, 1998; 583 
Voeks et al., 2002). Recombinant OAdVs can infect a variety of non-ovine cells such 584 
as rabbit, human and murine cells but cannot replicate within them (Khatri et al., 585 
1997; Hofmann et al., 1999; Löser et al., 2000; Xu et al., 2000; Kümin et al., 2002; 586 
Lockett & Both, 2002). They are not neutralized by polyclonal serum against HAdV-5 587 
(Xu & Both, 1998) and they can overcome pre-existing humoral immunity against 588 
HAdVs in vivo (Hofmann et al., 1999). A cosmid-based system proved useful for 589 
efficient generation of recombinant OAdVs and vectors could be rescued in an ovine 590 
fetal skin fibroblastic producer cell line (Löser et al., 2003). OAdV-7 carrying purine 591 
nucleoside phosphorylase (PNP), which converts the prodrug fludarabine into its 592 
activated form 2-fluoroadenine, was effective in vivo against prostate cancer 593 
progression upon prodrug addition (Voeks et al., 2002; Martiniello-Wilks et al., 2004). 594 
Moreover, recombinant OAdV-7 expressing ovalbumin showed efficacy in inducing 595 
antitumor response in a mouse model (Tang et al., 2012). OAdVs biosafety profile 596 
and their application as a gene delivery vectors were reviewed in the last decade 597 
(Both, 2004). 598 
4.7 MURINE AdV VECTORS 599 
The production of MAdV (genus Mastadenovirus, species Murine A, B, C) mutants 600 
started with the MAdV-1 (MAdV A species) E3 deleted recombinant (Beard & 601 
Spindler, 1996; Cauthen et al., 1999) and E1 deleted recombinant (Ying et al., 1998). 602 
MAdV-1 presents mouse endothelial cells tropism (Charles et al., 1998; Kajon et al., 603 
1998; Lenaerts et al., 2005) but it can also infect human endothelial cells (Nguyen et 604 
al., 1999) and it displays higher affinity for primary human smooth muscle cells than 605 
recombinant HAdV-5 (Lenaerts et al., 2009). MAdV-1 lacks the RGD motif in the 606 
penton base but it contains it in the fiber knob domain (Raman et al., 2009). The 607 
RGD motif was reported to play a role in MAdV-1 infection through αv integrins, which 608 
act as a receptor for the virus, and it was shown that cell surface heparan sulfate 609 
glycosaminoglycans (HSGAGs) are involved in MAdV-1 infection (Raman et al., 610 
2009). Conversely, the primary attachment of MAdV-1 is independent of CAR 611 
(Lenaerts et al., 2006). Distribution of MAdV-1 to the liver is markedly lower in 612 
intravenously injected immunodeficient mice than that observed with recombinant 613 
HAdV-5 (Lenaerts et al., 2009). Moreover, MAdV-1 has been used as an oncolytic 614 
vector proving that it is a suitable murine homolog model to test the mechanism of 615 
action of murine oncolytic AdV vectors in an immunocompetent, tumor-bearing host 616 
(Robinson et al., 2009). Furthermore, MAdV-1 has preference for ovarian carcinoma 617 
cell lines, probably because of their increased expression of the enzyme involved in 618 
HSPGs biosynthesis, therefore having the potential to be used in the oncolytic 619 
treatment of ovarian cancer (Lenaerts et al., 2012).  620 
 621 
5. CONCLUDING REMARKS AND FUTURE PERSPECTIVES 622 
The main limitation of clinically applied HAdV based vectors today is their failure in 623 
achieving high levels of efficient transduction in their target tissues. This is primarily 624 
due to the pre-existing NAbs leading to the rapid clearance of circulating vector and 625 
cellular immune responses resulting in the elimination of transduced cells, greatly 626 
limiting the expression of the transgene. These immunological responses most likely 627 
stem from the high frequency of HAdV exposure in multiple human populations 628 
across the globe, which results in immunological memory against HAdV serotypes 629 
that most of today’s vectors are based on. In order to circumvent this, several 630 
strategies have been developed for HAdVs, including molecular engineering of 631 
chimeric vectors or the use of low seroprevalent HAdV vectors. As an alternative, 632 
NHAdV vectors have been developed and are being tested in various non-human 633 
and human cell lines. Most of the NHAdV vectors have two important features which 634 
make them more appropriate than HAdV vectors: there is no or very low 635 
pathogenicity for their natural host, and there is no presence of pre-existing NAbs, 636 
CD4+ T cells and CD8+ CTLs against them. However, it should be noted that caution 637 
must be applied when using non-human primate AdVs, since their ability to infect 638 
human cells and their structural similarity could potentially result in anti-HAdV T-cell 639 
and/or NAb cross-reactivity with non-human primate AdV antigens. Different NHAdVs 640 
have specific tropism for different cell types, which makes them applicable in treating 641 
different diseases especially when the targeting of specific cells is required, and 642 
therefore they could extend the range of potential target tissues. Furthermore, the 643 
inability of NHAdVs to co-replicate with wt HAdVs, as well as the fact that they are 644 
replication defective in human cells, makes their vectors much safer than HAdV 645 
vectors. Many of the NHAdVs are able to tolerate longer sequences of exogenous 646 
DNA than HAdVs. For some of the NHAdVs there are low-cost propagation systems 647 
available, for example, chicken embryos for CELO virus (Laver et al., 1971; Michou 648 
et al., 1999). Despite these advantages, there are still many steps necessary before 649 
using the NHAdV vectors in the clinics. First challenge is to find the appropriate cell 650 
lines for efficient production. There are also safety issues compared to HAdVs such 651 
as the possible occurrance of interspecies adaptation. For example HAdV-4 is the 652 
only HAdV member of HAdV E species which is very similar to SAdVs from that 653 
group, indicating its zoonotic origin and molecular adaptation to its new host 654 
(Purkayastha et al., 2005a; Dehghan et al., 2013). As AdVs have co-evolved with 655 
their hosts (Benkö & Harrach, 2003; Davison et al., 2003), there is a possibility that 656 
humans and monkeys could be infected with the same AdVs, a concern when 657 
considering chimpanzee or simian AdV vectors for use in humans. Nevertheless, 658 
NHAdV vectors present great potential as effective gene therapy vehicles and will 659 
hopefully be part of the successful AdV vectors used in the clinics in the coming 660 
years. 661 
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